On the fly News and insights, exclusive to thefly.com

GRFS

Grifols

$22.74

0.38 (1.70%)

14:20
12/06/19
12/06
14:20
12/06/19
14:20

Grifols higher after new data show reduction in Alzheimer's progression

Grifols shares moved higher after the company presented its latest Alzheimer's clinical trial data at the Clinical Trials on Alzheimer's Disease Conference. New neuroimaging data results from the Ambar clinical trial show the reduction in the progression of the disease in patients with mild-to-moderate Alzheimer's disease, Grifols announced. The neuroimaging, which was measured by the FDG-PET1 technique, shows "positive" results particularly in patients receiving both albumin and immunoglobulin, according the company. In comparison with the placebo group, these patients had less reduction of brain glucose metabolism over the 14 months of the clinical trial. "This suggests that neuronal damage was reduced in these patients," Grifols said. The company added that it will soon meet with the FDA to discuss the Ambar clinical development program and the design of a successive Ambar II trial "that will deepen and complement the just-concluded one." Shares of Grifols are up 74c to $23.12 in afternoon trading.

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.